Organon VTAMA Cream Gains Strong AAD Guideline Support

Jersey City, New Jersey, U.S. | April 15, 2026

Organon has announced that its VTAMA® (tapinarof) cream, 1% has received a strong recommendation in the 2026 American Academy of Dermatology (AAD) guidelines for the treatment of pediatric atopic dermatitis (AD), marking a significant milestone in dermatology and evidence-based clinical care. The recommendation highlights VTAMA as the only steroid-free topical therapy supported by high-certainty evidence across all severities of atopic dermatitis in children aged 2 years and older, reinforcing its role as a first-in-class, nonsteroidal treatment option. This recognition underscores the growing importance of innovative, safe, and effective therapies for chronic inflammatory skin diseases, particularly in pediatric populations where treatment options have historically been limited.

Strong AAD Recommendation Validates Clinical Efficacy and Safety

The 2026 AAD pediatric atopic dermatitis guidelines represent the first comprehensive, pediatric-specific clinical recommendations issued by the organization, emphasizing the need for evidence-based, age-appropriate treatment strategies. VTAMA cream’s inclusion with a strong recommendation reflects robust clinical evidence from Phase 3 pivotal trials (ADORING 1 and ADORING 2), which demonstrated significant improvements in disease severity, symptom reduction, and overall patient outcomes.

The therapy’s favorable safety and tolerability profile further supports its use in children and adolescents, addressing key concerns related to long-term corticosteroid use. The guidelines recognize VTAMA as a high-certainty treatment option, enabling clinicians to confidently incorporate it into treatment plans across varying disease severities.

Steroid-Free Innovation Addresses Pediatric Treatment Gaps

Atopic dermatitis is one of the most common chronic skin conditions, affecting millions of children globally, and is characterized by symptoms such as itching, inflammation, redness, and skin barrier dysfunction. Traditional treatments often rely on corticosteroids, which can pose safety concerns with prolonged use, especially in pediatric patients. VTAMA cream, as an aryl hydrocarbon receptor (AhR) agonist, offers a novel, steroid-free mechanism of action that modulates immune responses and improves skin health without the risks associated with steroid therapies.

Its once-daily dosing, single formulation, and lack of restrictions based on disease severity or treatment duration make it a highly versatile and patient-friendly option. This innovation represents a critical step forward in addressing unmet clinical needs in pediatric dermatology, improving both adherence and quality of life for patients and caregivers.

Clinical and Regulatory Impact on Dermatology Practice

The strong recommendation from the AAD reinforces VTAMA’s growing role in modern dermatology treatment algorithms, particularly as healthcare systems shift toward evidence-based and patient-centric care models. The therapy was previously approved by the U.S. FDA for plaque psoriasis in adults and later expanded for atopic dermatitis in adults and pediatric patients aged 2 years and older, demonstrating its established regulatory and clinical foundation.

The inclusion in clinical guidelines further strengthens its market position and supports broader adoption among dermatologists. Additionally, the guidelines provide clinicians and caregivers with clear, evidence-driven direction for treatment selection, improving decision-making and standardizing care across patient populations.

Advancing Standards in Pediatric Dermatology

The recognition of VTAMA cream in the 2026 AAD guidelines represents a paradigm shift in the management of pediatric atopic dermatitis, highlighting the importance of nonsteroidal, targeted therapies in chronic inflammatory diseases. As the prevalence of atopic dermatitis continues to rise, innovations like VTAMA are expected to play a crucial role in improving long-term disease management and patient outcomes. By combining strong clinical evidence, regulatory validation, and patient-centric design, Organon is contributing to the evolution of dermatology care and setting new benchmarks for treatment standards.

Organon’s achievement with VTAMA cream underscores the critical role of clinical guideline endorsements in shaping therapeutic adoption and healthcare practices. With strong backing from the AAD and robust clinical data, VTAMA is well-positioned to become a leading treatment option for pediatric atopic dermatitis, offering a safe, effective, and innovative alternative to traditional therapies. As the industry continues to prioritize evidence-based medicine and improved patient outcomes, this milestone highlights the ongoing transformation of dermatology through scientific innovation and regulatory excellence.

Source: Organon press release